my question is then, on what basis were they making these statements in capital raises way back in 2015, 6 years ago
"2015"Finalizing the development and implementation of the 3D bioreactor-based manufacturing of our products..."
purely lip service repeated annually imo, with no tangible results, and now! suddenly they need it.
talk about vision, when the whole pharma industry has talked about manufacturing at scale is the No 1 issue for cell based therapies for years.
Where was SI leadership here?
Where did all the supposed research and $ end up?
Where's the report on current state of play?
No wonder dachopper thinks it didn't exist
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-575
-
- There are more pages in this discussion • 237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |